Short Interest in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Increases By 105.1%
by Scott Moore · The Cerbat GemAIM ImmunoTech Inc. (NYSEAMERICAN:AIM – Get Free Report) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 27,032 shares, a growth of 105.1% from the November 30th total of 13,177 shares. Approximately 0.9% of the shares of the stock are sold short. Based on an average trading volume of 60,771 shares, the days-to-cover ratio is currently 0.4 days. Based on an average trading volume of 60,771 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.9% of the shares of the stock are sold short.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the company. Maxim Group upgraded AIM ImmunoTech to a “strong-buy” rating in a research report on Friday, September 5th. Zacks Research downgraded AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.
View Our Latest Report on AIM ImmunoTech
AIM ImmunoTech Stock Down 2.3%
NYSEAMERICAN:AIM traded down $0.03 on Friday, reaching $1.25. The company’s stock had a trading volume of 51,670 shares, compared to its average volume of 51,297. AIM ImmunoTech has a 12-month low of $1.21 and a 12-month high of $36.00. The stock has a 50 day moving average price of $1.67 and a 200 day moving average price of $3.83. The firm has a market cap of $3.56 million, a price-to-earnings ratio of -0.06 and a beta of 1.19.
AIM ImmunoTech (NYSEAMERICAN:AIM – Get Free Report) last released its quarterly earnings results on Monday, November 17th. The company reported ($1.57) earnings per share for the quarter. The business had revenue of $0.03 million for the quarter. AIM ImmunoTech had a negative return on equity of 1,586.23% and a negative net margin of 14,062.50%. Equities research analysts expect that AIM ImmunoTech will post -0.3 EPS for the current fiscal year.
Hedge Funds Weigh In On AIM ImmunoTech
A hedge fund recently bought a new stake in AIM ImmunoTech stock. Corient Private Wealth LLC acquired a new position in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM – Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned 1.31% of AIM ImmunoTech as of its most recent filing with the SEC. Institutional investors and hedge funds own 12.02% of the company’s stock.
About AIM ImmunoTech
AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.
In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.